The Efficacy, Safety, and Cost Benefit of Olanzapine versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India

Background. The efficacy, safety, and cost benefit of olanzapine (OLN) when compared to aprepitant (APR) in the prevention of chemotherapy induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC) were evaluated. Methods. A prospective pilot study was done in chem...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Chemother Res Pract
Auteurs principaux: Babu, Govind, Saldanha, Smitha Carol, Kuntegowdanahalli Chinnagiriyappa, Lakshmaiah, Jacob, Linu Abraham, Mallekavu, Suresh Babu, Dasappa, Loknatha, Kiran, Pretesh Rohan, Sreevatsa, Aparna, Appachu, Sandhya, Unnikrishnan, Vineetha, Arroju, Venugopal
Format: Artigo
Langue:Inglês
Publié: Hindawi Publishing Corporation 2016
Sujets:
Clinical Study
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4748067/
https://ncbi.nlm.nih.gov/pubmed/26925265
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2016/3439707
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires